Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05733702 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinnova-IBD, a Prospective Cohort of Patients With Inflammatory Bowel Disease (IBD)

Study acronym: Clinnova-IBD
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv6
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Nov 2023 to Feb 1, 2024
    v5
  3. Start date: Sep 2023 to Nov 2023v4
  4. Start date: Mar 2023 to Sep 2023v3
  5. Primary endpoint revised
    • Study description expanded, about 6 words
    • Study title revised
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is part of the Clinnova program. This is a prospective cohort study including patients with IBD recruited at the time of a treatment change. At least 800 participants (recruited in France, Germany and Luxembourg) will be enrolled, of which 100 participants are expected to be recruited in Luxembourg with the present study protocol. The mission of Clinnova is to support the digitalization of healthcare and precision medicine by creating a data-enabling environment for accessing, sharing and analyzing interoperable, high-quality health data. The main hypothesis is that treatment change decided by clinicians is predictable using objective surrogate markers derived from clinical, epidemiological, and omics data. Identifying these objective markers may facilitate future treatment decisions, provide new insights on the molecular causes for differential treatment response, pathogenesis and progression, and potential pointers for improved personalized therapeutic interventions.
Trial Details
NCT Number NCT05733702
Lead Sponsor Luxembourg Institute of Health
Collaborators: Luxembourg National Research Fund, Centre Hospitalier du Luxembourg, Hôpitaux Robert Schuman, University of Luxembourg
Conditions
(from sponsor)		 Inflammatory Bowel Diseases
Related terms Inflammatory Bowel Diseases
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov